Perceptive Advisors LLC Alnylam Pharmaceuticals, Inc. Transaction History

Perceptive Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$120.42 - $169.29 $853,536 - $1.2 Million	-7,088 Reduced 3.94%	172,991 $25.2 Million
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $22.9 Million - $31.3 Million	180,079 New	180,079 $29.4 Million
Q1 2019 May 15, 2019	SELL	$72.76 - $93.45 $19.1 Million - $24.5 Million	-262,241 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$62.67 - $88.33 $58.6 Million - $82.7 Million	-935,753 Reduced 78.11%	262,241 $18.5 Million
Q3 2018 Nov 14, 2018	SELL	$87.52 - $122.67 $56.8 Million - $79.6 Million	-648,917 Reduced 35.14%	1,197,994 $105 Million
Q2 2018 Aug 14, 2018	BUY	$88.31 - $107.8 $50 Million - $61 Million	566,109 Added 44.2%	1,846,911 $182 Million
Q1 2018 May 15, 2018	SELL	$115.92 - $148.54 $5.8 Million - $7.43 Million	-50,000 Reduced 3.76%	1,280,802 $153 Million
Q4 2017 Feb 14, 2018	SELL	$114.49 - $139.98 $52.4 Million - $64.1 Million	-458,000 Reduced 25.6%	1,330,802 $169 Million
Q3 2017 Nov 14, 2017	BUY	$72.53 - $118.27 $130 Million - $212 Million	1,788,802	1,788,802 $210 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.